Ticagrelor (Brilique®) in combination with acetylsalicyclic acid

Assessment Status Rapid Review Complete
Drug Ticagrelor
Brand Brilique®
Indication Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
Assessment Process
Rapid review commissioned 29/02/2016
Rapid review completed 04/05/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.

 Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation